Stock Market & Financial Investment News

News Breaks September 12, 2012 08:41 EDT SNTS, PRX Santarus price target raised to $11 from $8 at Stifel Nicolaus Stifel Nicolaus increased its target on Santarus (SNTS) after the company's successful appeal against Par Pharmaceuticals (PRX), and its highly statistically significant Phase III results for Rifamycin SV MMX in traveler’s diarrhea. The firm thinks that Santarus' generic Zegerid will gain an extra $35M-$45M in annual sales as a result of the court decision, and it maintains a Buy rating on the stock. News For SNTS;PRX From The Last 14 Days Check below for free stories on SNTS;PRX the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 22, 2013 09:01 EDT PRX Par Pharmaceutical begins shipment of generic Atacand Subscribe for More Information May 17, 2013 10:36 EDT SNTS Leerink's major/specialty pharma analyst holds analyst/Industry conference call Subscribe for More Information May 10, 2013 09:06 EDT SNTS Santarus 4.25M share Spot Secondary priced at $18.25 Subscribe for More Information 09:00 EDT SNTS Santarus falls 7.3% Subscribe for More Information May 9, 2013 16:02 EDT SNTS Santarus files to sell common stock for Cosmo Technologies, no amount given Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.